HomeCompareHTBX vs VICI

HTBX vs VICI: Dividend Comparison 2026

HTBX yields 84.03% · VICI yields 6.57%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HTBX wins by $993.9K in total portfolio value
10 years
HTBX
HTBX
● Live price
84.03%
Share price
$2.38
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.98M
Annual income
$593,470.68
Full HTBX calculator →
VICI
VICI Properties Inc.
● Live price
6.57%
Share price
$27.12
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$988.8K
Annual income
$623,261.32
Full VICI calculator →

Portfolio growth — HTBX vs VICI

📍 HTBX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHTBXVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HTBX + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HTBX pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HTBX
Annual income on $10K today (after 15% tax)
$7,142.86/yr
After 10yr DRIP, annual income (after tax)
$504,450.08/yr
VICI
Annual income on $10K today (after 15% tax)
$558.67/yr
After 10yr DRIP, annual income (after tax)
$529,772.12/yr
At 15% tax rate, VICI beats the other by $25,322.04/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HTBX + VICI for your $10,000?

HTBX: 50%VICI: 50%
100% VICI50/50100% HTBX
Portfolio after 10yr
$1.49M
Annual income
$608,366.00/yr
Blended yield
40.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

HTBX
Analyst Ratings
8
Buy
Consensus: Buy
Altman Z
-22.5
Piotroski
2/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+16.5% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HTBX buys
0
VICI buys
0
No recent congressional trades found for HTBX or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHTBXVICI
Forward yield84.03%6.57%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$1.98M$988.8K
Annual income after 10y$593,470.68$623,261.32
Total dividends collected$1.73M$948.4K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: HTBX vs VICI ($10,000, DRIP)

YearHTBX PortfolioHTBX Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$19,103$8,403.36$11,368$948.43+$7.7KHTBX
2$35,444$15,003.03$13,339$1,493.16+$22.1KHTBX
3$63,940$26,014.99$16,326$2,426.21+$47.6KHTBX
4$112,276$43,860.35$21,123$4,112.15+$91.2KHTBX
5$192,114$71,978.72$29,379$7,368.23+$162.7KHTBX
6$320,666$115,104.62$44,804$14,191.64+$275.9KHTBX
7$522,671$179,557.63$76,658$29,972.12+$446.0KHTBX
8$832,781$273,523.56$150,894$71,015.81+$681.9KHTBX
9$1,298,375$407,299.36$350,814$193,582.47+$947.6KHTBX
10$1,982,732$593,470.68$988,809$623,261.32+$993.9KHTBX

HTBX vs VICI: Complete Analysis 2026

HTBXStock

Heat Biologics, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. Heat Biologics, Inc. has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was incorporated in 2008 and is headquartered in Morrisville, North Carolina.

Full HTBX Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this HTBX vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HTBX vs SCHDHTBX vs JEPIHTBX vs OHTBX vs KOHTBX vs MAINHTBX vs NNNHTBX vs EPRTHTBX vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.